Table 2 Clinico-pathological features of EBV + nodal PTCL, NOS with cytotoxic phenotype.
ID # | DL07 | DL08 | DL14 | DL24 | DL34 | DL35 | DL63 |
|---|---|---|---|---|---|---|---|
Sexe | F | M | F | M | M | M | M |
Age | 57 | 81 | 66 | 50 | 22 | 48 | 34 |
Stage | III | IV | IV | I | III | IV | na |
Extranodal sites | ENT | ENT | ENT, BM | – | Liver, BM | na | |
B-symptoms | + | + | + | – | + | – | na |
LDH (increased) | + | + | + | na | + | – | na |
IPI | 2 | 4 | 3 | na | 2 | 2 | na |
Cytopenia ≥ 1 lineage | – | + | + | na | + | – | na |
Medical history | CHL | – | DLBCL EBV + , AHAI | B hepatitis | glomerulonephritis | – | na |
Reccurence of disease in the LN | na | na | LN cervical | na | LN mediastinal | LN (NOS) | na |
Treatment | chemo | no treatment | chemo | chemo | chemo + allo HSCT | chemo+allo HSCT | na |
OS time (months) | 3 | 37 | 25 | 1 | 123 | 75 | na |
Outcome | DOD | DOD | Died of treatment retated complication (infection) | Died of treatment retated complication (infection) | DOD | alive | na |
LN site biopsy | not specified | peripancreatic | axillary | cervical | cervical | mesenteric | cervical |
Infiltration pattern | diffuse | diffuse | diffuse | diffuse | diffuse | interfollicular | diffuse |
Tumor cell size | medium to large | medium to large | medium | large | medium to large | medium to large | large |
Necrosis | ++ | ++ | – | + | ++ | – | – |
Angiocentricity | + | – | – | – | + | – | – |
Microenvironment | histiocytes | 0 | polymorphic | 0 | polymorphic | polymorphic | histiocytes |
